The West African nation stands ready to solve the geographic mismatch between research capacity and patient population.
From the Journals
L-glutamine is not only an alternative to hydroxyurea but an additive therapy for patients with suboptimal response, the researchers said.
WASHINGTON – Fewer than one in five adults experienced treatment-related adverse events and no secondary malignancies have been observed,...
WASHINGTON – Hospitalizations and transfusions were down by about two-thirds in this severely affected group.
WASHINGTON – “This is a dream deferred” for patients and families affected by sickle cell disease.
News from the FDA/CDC
Mircera is now indicated for dialysis-related anemia in patients aged 5-17 years with chronic kidney disease.
Eltrombopag is being evaluated for first-line treatment of severe aplastic anemia with standard immunosuppressive therapy.
BOSTON – New study explores mechanisms beyond those already known or suspected.
This is the first product approved as biosimilar to epoetin alfa.